Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.09.017Source: DataRank Database

Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant is a research paper published in Journal of Cystic Fibrosis (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.33)OA: bronzeTopics (30)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Lauren Bartlett ORCID,Jennifer S. Guimbellot ORCID,T. Milinic ORCID,Nora Burdis,Eliana R Gill ORCID

Live enrichment

PubMed:37798159 PMC:PMC10987391 OpenAlex:https://openalex.org/W4387299199

National Institutes of Health

Grant: K23HL138154

National Institutes of Health

Grant: R03HL158728

National Institutes of Health

Grant: T32HL007287

National Institutes of Health

Grant: R01NR020470

National Institutes of Health

Grant: T32016913

Cystic Fibrosis Foundation

Grant: LEASE17AB3

Cystic Fibrosis Foundation

Grant: RAMOS22A0

NIDDK NIH HHS

Grant: P30 DK089507

NHLBI NIH HHS

Grant: T32 HL125195

NINR NIH HHS

Grant: T32 NR016913

American Thoracic Society

FWCI

0.33

Citation Percentile

0.6%

Citation Trend

2024

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.cysticfibrosisjournal.com/article/S1569-1993(23)00921-9/pdf

publisherhttps://www.cysticfibrosisjournal.com/article/S1569-1993(23)00921-9/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199323009219?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199323009219?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2023.09.017

Fields of Study

Cystic Fibrosis Research AdvancesMedicine

MeSH Terms

AdultAminophenolsCystic FibrosisDrug CombinationsFemaleHumansIndolesMaleMiddle AgedPyrazolesPyridinesPyrrolesPyrrolidinesQuality of LifeSurveys and QuestionnairesQuinolonesLung TransplantationBenzodioxolesChloride Channel AgonistsTransplant Recipients

Keywords

IvacaftorCystic fibrosisMedicineCystic fibrosis transmembrane conductance regulatorLung transplantationLungIntensive care medicineInternal medicine